Forus’ $150 million Series C round was led by Bain Capital Ventures, with participation from Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Avra, Human Capital, Neo, Vast Ventures and SV Angel. The post Forus Secures $150M Series C, Reaches $3B Valuation appeared first on MedCity News.

LEP Biomedical is developing a dissolvable implant that replaces weeks of self-administered eye drops after glaucoma surgery, aiming to fix the compliance problems that drive surgical failure rates as high as 40%. The post This Startup Wants to Make Glaucoma Surgery Recovery Easier appeared first on MedCity News.

The path forward requires much more than whack-a-mole point solution replacement. It requires a more critical look at redesigning the entire workflow architecture The post Is Radiology at a Structural Breaking Point? What Will Move It to a Better Future? appeared first on MedCity News.

[Sponsored] The 2026 Healthcare AI Readiness Index, a new report by Cotiviti and MedCity News, is based on a survey of 70 healthcare leaders over the summer and shares candid views of how they balance harnessing AI with operational, regulatory and security challenges it creates. Download the report today! The post Survey Reveals AI Adoption is Accelerating in Healthcare, But Readiness is Not appeared first on MedCity News.

Rep. Frank Pallone, Jr., is seeking information from six IDR entities amid concerns about No Surprises Act arbitration practices and rising healthcare costs. The post US Representative Scrutinizes Practices of IDR Entities appeared first on MedCity News.

Early intervention based on accurate diagnosis of both metabolic risk factors and acute cardiac events could help make the difference between life and death for women. The post Advancing Women’s Heart Health Through Prevention and Rapid Diagnosis appeared first on MedCity News.

GSK gained rights to a Hutchmed antibody-targeted therapy conjugate, or ATTC. This new type of targeted therapy blocks two cancer-driving proteins and will initially be developed for lung, colorectal, and pancreatic cancers. The post GSK Pays $110M for Phase 1-Ready Hutchmed Asset in a New Class of Cancer Drugs appeared first on MedCity News.

The House VA Committee voted 19-0 to subpoena Oracle Health executives Larry Ellison and Mike Sicilia after learning the VA’s EHR contract ballooned from $10 billion to $27 billion — despite Oracle’s promise to Congress that it would absorb any costs beyond the original cap. The post Oracle Health Execs Subpoenaed After VA Contract Costs Nearly Triple appeared first on MedCity News.

Ionis Pharmaceuticals’ zilganersen, brand name Zanvastro, is the first disease-modifying therapy approved for the neurological disorder Alexander disease. While Ionis has experience developing medicines for rare neuroscience indications, Zanvastro will be the first neurology product the company brings to the market without a commercialization partner. The post FDA Approves Ionis Pharma Drug, the First for Ultra-Rare Alexander Disease appeared first on MedCity News.

Three things ski patrol can teach about building a business The post Bringing Ski Patrol Lessons to Healthtech Entrepreneurship appeared first on MedCity News.

Judi Health expanded its healthcare network to offer specialized virtual care for cancer, autoimmune and GI conditions while helping employers reduce overall healthcare costs. The post Judi Health Taps Color Health, WellTheory, Cylinder for Clinical Ecosystem appeared first on MedCity News.

A roundup of the seven most notable hospital mergers and acquisitions announced or completed this summer, including Prisma Health’s acquisition of Erlanger Health and Sanford Health’s purchase of North Memorial Health The post 7 Hospital Mergers from Summer 2026 appeared first on MedCity News.

Ultragenyx Pharmaceuticals’ apazunersen did not meet the goals of its Phase 3 test in Angelman syndrome, a rare genetic neurological disorder with no FDA-approved therapies. The disappointing result has some readthrough to Ionis Pharmaceuticals and Oak Hill Bio, each in clinical development with Angelman drugs designed to work in a similar way as Ultragenyx’s failed molecule. The post Ultragenyx Trial Failure Revives Debate About How to Treat a Rare Neuro Disorder appeared first on MedCity News.

This shift is not about replacing clinical care with tradition. It is about recognizing that healing in Native communities has always been deeply connected to culture. The post Healing Through Heritage: Why Culturally Grounded Recovery Matters on Tribal Lands appeared first on MedCity News.

Selio Medical developed an FDA-cleared hydrogel device that seals CT-guided lung biopsy punctures before they can cause pneumothorax — a collapsed lung complication that affects up to a third of the 800,000+ such biopsies performed annually in the U.S. The post This Device Could Prevent Lung Biopsy’s Most Common — and Costly — Complication appeared first on MedCity News.